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Objectives The purpose of this study was to systematically compare clinical outcomes of patients treated with thrombolysis
with those without treatment in a multi-year, multicenter cohort of strokes after cardiac catheterization.
Background Ischemic strokes after cardiac catheterization procedures, although uncommon, lead to the morbidity and mor-
tality of thousands of patients each year. Despite the availability of Food and Drug Administration–approved
thrombolytic therapy for acute ischemic stroke since 1996, thrombolysis remains unestablished in the setting of
cardiac catheterization, owing to unique concerns regarding safety and efficacy.
Methods Consecutive cases of ischemic stroke after cardiac catheterization were abstracted retrospectively and reviewed
by clinicians at 7 major North American academic centers with acute stroke teams. Safety and efficacy outcome
measures were pre-defined.
Results A total of 66 cases of ischemic strokes after cardiac catheterization were identified over 3 to 4 years; 12 (18%) were
treated with thrombolysis, consisting of 7 intravenous and 5 intra-arterial recombinant tissue plasminogen activator
cases. Improvement in stroke symptoms, as measured by the primary efficacy measure of median change in Na-
tional Institutes of Health Stroke Scale score from baseline to 24 h, was greater in treated versus nontreated cases (p
 0.001). Additional secondary measures of efficacy also showed better outcomes in the treated group. There were
no significant differences in bleeding events, defined as symptomatic intracerebral hemorrhage, hemopericardium, or
other systemic bleeding resulting in hemodynamic instability or blood tranfusions. Mortality rates were also similar.
Conclusions Thrombolysis might improve early outcomes after post-catheterization strokes and seems safe in this context.
Emergent cerebral revascularization should be a routine consideration. (J Am Coll Cardiol 2008;51:906–11)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.068v
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eore than 2 million cardiac catheterization procedures are
erformed in the U.S. annually. Although strokes after
ardiac catheterization (SCCs) are relatively rare, this high
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eptember 23, 2007.olume of cardiac catheterizations in the U.S. leads to
housands of SCCs each year. Rates of SCCs, including
oth ischemic and hemorrhagic subtypes, range widely from
.07% to 7.0%. Large contemporary registries of exclusively
iagnostic and invasive coronary procedures report rates
rom 0.07% to 0.38%, and smaller studies of other invasive
tudies report higher rates (1).
See page 912
The majority of SCCs are likely ischemic infarcts, for
hich there is Food and Drug Administration–approved
herapy. Intravenous thrombolytic therapy with recombi-
ant tissue plasminogen activator (rt-PA) within 3 h of
schemic stroke symptom onset has been shown to be
fficacious and cost-effective in the general stroke popula-
ion (2,3). Unfortunately, this proven therapy is provided to
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March 4, 2008:906–11 Strokes After Cardiac Catheterizationnly a small fraction of all ischemic strokes, primarily owing
o delayed presentation to emergency departments (4). In
ddition, intra-arterial thrombolytic drugs and devices
ight be effective at later time windows (5,6). The SCCs
ypically occur in hospitalized patients under close observa-
ion and therefore offer the potential for early and rapid
etection and treatment. However, there is debate about the
afety and efficacy of thrombolysis in the peri- and post-cardiac
atheterization setting (7,8).
No study has yet attempted to systematically collect data
n all SCCs and characterize their treatment in either a
ingle or multicenter cohort. Therefore, we designed a
etrospective cohort study of consecutive SCCs managed at
ajor academic stroke centers with organized stroke teams,
nd we compared outcomes of patients treated with throm-
olysis to those without treatment. We hypothesized that
1) intravenous and intra-arterial thrombolytic therapy for
trokes in the cardiac catheterization setting would be
elatively safe, with complication rates comparable to SCCs
ot receiving thrombolytic therapy, and (2) patients treated
ith thrombolytic therapy would have better outcomes than
hose not treated with thrombolysis.
ethods
e invited 15 academic centers with stroke teams to
ontribute, and 7 centers (National Institutes of Health
troke Center, New York Presbyterian Hospital-Weill,
niversity of Calgary, University of California Los Angeles,
niversity of Cincinnati, University of Iowa, University of
ennsylvania) elected to participate. A designated principal
nvestigator at each participating center identified potential
atients by reviewing all medical records or their existing
troke databases with both a stroke diagnosis (International
lassification of Diseases of the World Health Organization-
th edition [ICD-9] codes: 997.02, 436, 433.0–433.3,
33.8–434.1, and 434.9) and a cardiac procedure (ICD-9
odes: 36.01–337.21–37.23, 37.26, 37.27, 37.34, 88.52–
8.57) during the same admission. Cardiac procedures
ncluded left heart catheterization, coronary angiography,
oronary angioplasty or stenting, left ventriculography, val-
uloplasty, patent foramen ovale/atrial septal defect (PFO/
SD) closure, and electrophysiologic diagnostic and abla-
ive studies. Seven centers collected cases from September
000 to September 2003, and 1 center collected data from
eptember 2000 to September 2004. At each center, all
onsecutive ischemic strokes within 36 h of cardiac cathe-
erization were included, regardless of the indication for
ardiac catheterization, post-stroke treatment decision, or
utcome. A clinician collected the following de-identified
nformation on standardized case report forms: demo-
raphic information, medical history, cardiac catheteriza-
ion technical details, post-stroke course, stroke localization
nd etiology, complications, and clinical outcome. National
nstitutes of Health Stroke Scale (NIHSS) scores were
etermined with data in the medical records, which is ionsidered a highly reliable ap-
roach (9). This protocol re-
eived institutional review board
pproval at each institution un-
er expedited or exempted
echanisms. Data were entered
nto spreadsheets with double-
ntry.
The pre-defined primary effi-
acy outcome measure was the
hange in NIHSS score from
aseline to 24 h in the rt-PA
roup, compared with non–
t-PA group. Categorical analy-
es were also performed, comparing the proportions of
atients with complete resolution (NIHSS  0) or 5-
oint improvement from baseline to 24 h in both groups.
e also planned secondary analyses excluding the mildest
troke cases (NIHSS 5), in anticipation of these patients
eing excluded from thrombolytics (10). Additional pre-
pecified secondary outcome measures were 7- and 30-day
IHSS scores, discharge modified Rankin Scores (mRS),
nd death during hospital stay.
The pre-defined primary safety measures were the rate of
ignificant bleeding events and the rate of mortality during
he hospital stay, comparing the rt-PA to the non–rt-PA
roup. Data on all bleeding events were collected, including
uncture site hemorrhage, retroperitoneal hemorrhage, he-
opericardium, and symptomatic and asymptomatic intra-
erebral hemorrhage (ICH) within 48 h of stroke. Signifi-
ant bleeding events were defined as those requiring blood
ransfusion or causing hemodynamic instability and those
pecifically consisting of hemopericardium or symptomatic
CH. The ICHs were defined as “symptomatic” if the patient
ad any symptoms attributed to a new ICH by the local
rincipal investigator. All transfusions given during the hospi-
al stay were recorded on case report forms to ensure that
leeding events were not missed due to lack of documentation.
tatistical analysis. Patient characteristics were compared
ith unpaired t tests (age) and Wilcoxon rank sum test for
ariables that were not normally distributed (NIHSS and
ime factors). Chi-square or Fisher exact tests were used for
ategorical variables, depending on individual cell sizes.
Power calculations were difficult a priori. Assuming alpha
.05, power  80%, and planned convenience sample of
pproximately 100 patients, we estimated an ability to detect
5-point difference in NIHSS (primary efficacy outcome)
etween rt-PA cases and control subjects if only 9 cases
ere treated with rt-PA. A smaller total would be needed if
ore patients received thrombolytics.
esults
total of 66 SCCs were identified; 12 (18%) were treated
ith thrombolysis: 7 with intravenous rt-PA, and 5 with
Abbreviations
and Acronyms
CT  computed
tomography
ICH  intracerebral
hemorrhage
NIHSS  National
Institutes of Health Stroke
Scale
rt-PA  recombinant tissue
plasminogen activator
SCC  stroke after cardiac
catheterizationntra-arterial rt-PA. Age, medical comorbidities, and car-
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Strokes After Cardiac Catheterization March 4, 2008:906–11iac procedure characteristics were similar between treat-
ent and nontreatment groups (Table 1).
Comparing the treatment and nontreatment groups,
ates of heparin use (92% vs. 69%; p  0.31) and
lycoprotein (GP) IIb/IIIa inhibitor use (25% vs. 20%; p
0.49) were similar. One case in the no rt-PA group
eceived bivalirudin during the cardiac catheterization
rocedure. In 55 patients whose activated partial throm-
oplastin times (aPTTs) were recorded before the diag-
osis or treatment of SCC, 19 (35%) had a prolonged
PTT (40 s), including 2 of 7 (29%) treated IV, 1 of 5
aseline Characteristics
Table 1 Baseline Characteristics
Thrombolysis
(n  12)
No Thrombolysis
(n  54) p Value
Patient characteristics
Age (yrs) 72 8 67 13 0.19
Female 6 (50%) 23 (43%) 0.50
White 8 (72%) 38 (75%) 1.00
Diabetes 3 (25%) 18 (33%) 0.74
Hypertension 9 (75%) 38 (70%) 1.00
Hyperlipidemia 8 (67%) 26 (49%) 0.35
CAD 8 (67%) 33 (61%) 1.00
CHF 1 (8%) 8 (15%) 1.00
AF 2 (17%) 14 (26%) 0.72
History of PVD 4 (33%) 8 (15%) 0.21
History of stroke 2 (17%) 5 (9%) 0.60
History of TIA 2 (17%) 5 (9%) 0.60
Procedural characteristics
Angiogram 10 (83%) 48 (86%) 1.00
Angioplasty 3 (25%) 20 (36%) 0.74
Valvuloplasty 0 (0%) 1 (2%) 1.00
EP study or ablation 2 (17%) 5 (9%) 0.60
PFO/ASD closure 0 (0%) 1 (2%) 1.00
Fluoroscopy time
(median) (min)
16 24 0.20
Procedure time
(median) (min)
65 75 0.73
F  atrial fibrillation; CAD  coronary artery disease; CHF  congestive heart failure; EP 
lectrophysiology; PFO/ASD  patent foramen ovale/atrial septal defect; PVD  peripheral
ascular disease; TIA  transient ischemic attack.
Clinical Outcomes After Thrombolysis Versus No
Table 2 Clinical Outcomes After Thrombolys
Thromb
Total cohort n 
Baseline NIHSS, median (range) 10.5
24-h NIHSS, median 4.5
Change baseline–24-h*† 6 (
7-day NIHSS, median 3
Change baseline–7-day* 6.5 (
Excluding baseline NIHSS 5 n 
Baseline NIHSS, median (range) 10.5
24-h NIHSS, median 4.5
Change baseline–24-h*† 6 (
7-day NIHSS, median 3
Change baseline–7-day* 6.5 (*Negative numbers represent improvement; positive numbers represent wor
NIHSS  National Institutes of Health Stroke Scale score.20%) treated IA, and 16 of 43 (37%) not treated with
hrombolytics (p  0.89). In 58 patients whose interna-
ional normalized ratios (INRs) were recorded before
iagnosis or treatment of SCC, 3 (5%) had an abnormal
NR (1.7), including none treated with rt-PA and 3 of
6 (7%) not treated with thrombolytics (p  1.00).
ctivated clotting time data were not recorded.
As expected, patients who were treated with thrombolysis
ad more severe strokes (p  0.01). Median baseline
IHSS scores were 10.5 in the rt-PA group and 6 in the
on–rt-PA group.
The median time from symptom onset to treatment was
42 (range 54 to 305) min in the treated group, including 90
range 75 to 168) min in the intravenous group and 240
range 54 to 305) min in the intra-arterial group. Three
t-PA cases received additional stroke therapies, consisting
f intra-arterial clot retrieval with a microsnare device,
ntra-arterial abciximab, and a possible neuroprotective
gent (in the context of a trial).
Efficacy results are summarized in Table 2. The median
hange in NIHSS score from baseline to 24 h, the primary
utcome measure of the study, was 6 in the rt-PA group and
in the non–rt-PA group (p  0.001). Either complete
esolution (NIHSS  0) or 5-point improvement in
IHSS score over the first 24 h was seen in 58% of treated
atients and 15% of untreated patients (risk ratio [RR] 
.9, 95% confidence interval [CI] 1.8 to 8.8; p  0.003).
he median change in NIHSS from baseline to 7 days was
.5 in the rt-PA group and 1.5 in the untreated group (p 
.004).
In secondary analyses excluding the mildest strokes (base-
ine NIHSS 5), a relative contraindication to rt-PA and a
ey determinant of clinical outcome (11), the initial differ-
nce in baseline NIHSS scores was no longer significant
p 0.46) and the change in NIHSS score from baseline to
4 h was still significantly greater with thrombolysis (me-
ian 6 vs. 1; p  0.008). In this subset, there was either
omplete resolution (NIHSS  0) or 5-point improve-
ent over the first 24 h in 58% of treated patients and 21%
mbolysis
rsus No Thrombolysis
No Thrombolysis p Value
n  54
6 (1–34) 0.01
3 (0–33) 0.69
0 (6–7) 0.001
3 (0–33) 0.55
1.5 (23–7) 0.004
n  33
8 (5–34) 0.46
6 (1–33) 0.17
1 (6–7) 0.008
4 (0–33) 0.41
3 (23–7) 0.07Thro
is Ve
olysis
12
(5–29)
(0–29)
17–0)
(0–29)
19–0)
12
(5–29)
(0–29)
17–0)
(0–29)
19–0)sening. †Primary outcome measure.
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March 4, 2008:906–11 Strokes After Cardiac Catheterizationf untreated patients (RR  2.8, 95% CI 1.2 to 6.2; p 
.017). The change in NIHSS score from baseline to 7 days
as marginally better with treatment (median 6.5 vs. 3; p 
.07).
Rates of discharge mRS 0 to 1 (30% rt-PA vs. 28%
on–rt-PA; p  0.72) were not significantly different
etween the 2 groups. Analysis of change in NIHSS over 30
ays was not performed, owing to few 30-day data points.
The primary safety end points did not differ between
roups. Specifically, mortality rates were 8% in the rt-PA
nd 7% in the non–rt-PA groups (p  0.91), including 1
eurologic death due to cerebral herniation in each group
8% vs. 2%; p  0.33). There were no symptomatic ICHs.
here were 6 asymptomatic hemorrhages, including 3 in the
t-PA group (Table 3) and 3 in the untreated group (25% vs.
%; p 0.037). Minor puncture site bleeding rates were not
ignificantly different (8% rt-PA vs. 7% untreated; p 
.92). There were no retroperitoneal hemorrhages, hemoperi-
ardium, other sites of bleeding, or transfusions. Three patients
n the rt-PA group had an elevated aPTT after the cardiac
rocedure, but none had a hemorrhagic complication.
iscussion
hrombolysis has been established as an effective treatment
or acute ischemic stroke, but its benefit and risk for
schemic strokes specifically in the cardiac catheterization
etting have not previously been investigated (7). Bleeding
Cases With ICH After Thrombolysis for SCC
Table 3 Cases With ICH After Thrombolysis
Age 9 Years NIHSS at Baseline
#1 (rt-PA) 76 29
#2 (rt-PA) 72 24
#3 (rt-PA) 72 15CT  computed tomography; ICH  intracerebral hemorrhage; NIHSS  Na
plasminogen activator; SAH  subarachnoid hemorrhage; SCC  stroke afteisks of thrombolysis might be increased after cardiac
atheterization, owing to the recent invasive procedure and
he concurrent administration of antithrombotic medica-
ions. Moreover, thrombi leading to SCCs arguably might
e less likely than other strokes to respond to thrombolysis
n the basis of presumptions about their likely composition.
or example, dislodged aortic arch plaque might be calcified
nd fibrin-dense and therefore not amenable to lysis. Alter-
atively, calcific thrombi might partially lyse, leading to
ownstream emboli (12). In addition, air emboli and me-
allic emboli might not respond to thrombolysis at all
1,7,13,14).
In contrast, fresh thrombus on the tip of a guidewire
ight be easier to destabilize than other clot etiologies.
imited evidence suggests that the broad category of car-
ioembolic etiologies might be particularly amenable to
hrombolysis (15). In addition, regardless of etiology, su-
erimposed fresh fibrin deposition on atheroma or other
omponents might make these emboli at least partially
esponsive to thrombolysis. Autopsy studies of coronary
rtery bypass graft patients with strokes suggest that larger
lots causing territorial infarcts tend to be particularly rich in
latelets and fibrin. However, specific data on the thrombus
omposition of ischemic SCCs are lacking. Thrombolysis
as been shown to be equally effective across the major
troke subtypes (small-vessel, large-vessel, and cardioem-
olic) (2), and therefore the pathogenesis of SCCs might be
rrelevant with respect to this treatment decision.
CC
H Size Symptomatic? CT Scan
8 ml No
1 ml No
ld SAH Nofor S
IC
1
Mitional Institutes of Health Stroke Scale; rt-PA  recombinant tissue
r cardiac catheterization.
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Strokes After Cardiac Catheterization March 4, 2008:906–11Case reports and small series consisted of 39 SCCs
eported in the published data as of April 2007, including 1
atient treated with intravenous thrombolysis alone, 2
atients receiving combined intravenous/intra-arterial rt-
A, and the rest treated via the intra-arterial approach
1,8,16–19). Independent function or full recovery was
chieved in 23 (61%) of the 38 cases commenting on
unctional outcome. These reports must be interpreted with
reat caution, owing to likely publication bias toward
ositive clinical outcomes. We report the first systematically
ollected data on every consecutive SCC and its treatment
n either a single or multicenter cohort, thereby possibly
inimizing these biases.
In our cohort, 18% were treated with thrombolytics, a far
reater proportion than in the general stroke population
20). Moreover, patients were treated at a median door-to-
eedle time of 90 min with intravenous rt-PA and 240 min
ith intra-arterial therapy, suggesting comparable or better
peed than major thrombolysis trials (5,21). Our primary
nalysis showed a statistically and clinically significant early
mprovement in stroke severity in NIHSS score by 24 h.
hange in NIHSS score at 24 h was 1 of the most powerful
iscriminators of the rt-PA effect in the NINDS (National
nstitute of Neurological Disorders and Stroke) trial (22,23)
nd is likely to be a good surrogate marker for better
ong-term clinical outcome (24). Similar improvements
ere observed from baseline to 7 days.
There were no symptomatic ICHs in our treated cases, as
ompared with 6.4% in the only randomized trial of
ntravenous rt-PA (NINDS Part 1 and 2) (2) and 10% in
he only randomized trial of intra-arterial thrombolysis
PROACT II) (5). A series of intra-arterial rt-PA SCC
ases at a single center (n  22) reported 3 (14%) symp-
omatic ICHs (19), comparable to the PROACT II rate.
ur cohort had a 25% asymptomatic hemorrhage rate, also
imilar to the rates (26% to 42%) seen in major intra-arterial
rials (25).
There were also no significant systemic bleeding events
nd no increase in even minor puncture site bleeding rates,
n the rt-PA group. This is consistent with the substantial
ublished experience with intra-arterial stroke therapies
equiring groin site arterial puncture (5,26) and case series
tudies of post-surgical thrombolysis (27,28). Our sample of
atients treated with thrombolysis is too small to estimate
leeding risks with precision but, in combination with prior
eports, suggests that this risk is low. We also cannot
ddress specific subgroups known to have higher symptom-
tic ICH risk, such as elderly patients, although 2 large
bservational studies of ischemic stroke patients suggest that
lderly patients benefit from thrombolysis despite increased
CH risk (1).
Antithrombotic medications administered during the
ardiac catheterization procedure might influence the deci-
ion to treat with thrombolytics. Heparin, if associated with
 prolonged aPTT, is a contraindication for intravenous
t-PA in the standard protocol (2). However, heparin isoutinely administered in intra-arterial thrombolysis cases
5,26). Therefore, intra-arterial rt-PA or mechanical revas-
ularization might be a consideration in this situation,
epending on the dose and timing of heparin received.
urthermore, the risks of rt-PA for stroke in the presence of
ther antithrombotic agents commonly used in cardiac
nterventional procedures, such as GP IIb/IIIa inhibitors, is
ot known. The low intracranial and systemic hemorrhage
ates in our cohort suggest that periprocedural use of these
ntithrombotic agents does not absolutely militate against
hrombolysis. Ongoing stroke trials using rt-PA combined
ith GP IIb/IIIa inhibitors might further define these risks.
Our findings suggest that thrombolysis might improve
arly outcome of SCC and seems relatively safe in this
ontext. This study has the limitations inherent in its
etrospective design and modest sample size. For example,
e could not control for all potential baseline differences
etween treated and untreated groups in this observational
ohort. However, this systematically collected, multicenter
ohort of consecutive SCC patients provides compelling
ata to suggest that post-catheterization stroke patients
ight be opportune candidates for acute intervention, and
mergent cerebral revascularization should be a routine
onsideration. Future large, prospective registries to further
haracterize this population are recommended.
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